Bunion, Forefoot Surgery, Hindfoot Fusion, Metatarsophalangeal Fusion, Midfoot Fusion, Total Ankle Arthroplasty
Conditions
Brief summary
This is a Phase 3, multicenter, randomized, double blinded, active controlled study in approximately 81 subjects undergoing lower extremity surgeries with combined sciatic and adductor canal nerve block.
Interventions
DRUGEXPAREL 13.3Mg/mL Suspension for Injection
Combined Sciatic and Adductor Canal Nerve Block with EXPAREL mixed with Bupivacaine (Single Dose)
DRUGBupivacaine Hydrochloride
Combined Sciatic and Adductor Canal Nerve Block with Bupivacaine HCL
Sponsors
Pacira Pharmaceuticals, Inc
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Caregiver)
Masking description
Double-blind
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Healthy adult male or female volunteers ages 18 or older 2. American Society of Anesthesiologists (ASA) physical status 1, 2 or 3. 3. Able to provide informed consent, adhere to the study schedule, and complete all study assessments. 4. Body Mass Index ≥18 and ≤40 kg/m2
Exclusion criteria
1. Allergy, hypersensitivity, intolerance, or contraindication to any of the study medications for which an alternative is not named in the protocol (eg, amide-type local anesthetics, opioids, bupivacaine, NSAIDs) 2. Documented history of long-term diabetes, renal (serum creatinine level \>2mg/dL \[176.8 μmol/L\]) or hepatic dysfunction (serum alanine or aspartame transferase \> 3 times the upper limit of normal), coagulation or bleeding disorder and severe peripheral vascular disease 3. Concurrent painful physical condition that may require analgesic treatment (such as long-term, consistent use of opioids) in the post dosing period for pain and which, in the investigator's opinion may confound the post dosing assessments 4. History of, suspected, or known addiction to or abuse of illicit drug(s), prescription medicine(s), or alcohol within the past 2 years 5. Administration of an investigational drug within 30 days or 5 elimination half-lives of such investigational drug, whichever is longer, prior to study drug administration, or planned administration of another investigational product or procedure during the subject's participation in this study 6. Previous participation in EXPAREL study 7. Uncontrolled anxiety, schizophrenia, or other psychiatric disorder that, in the opinion of the investigator, could interfere with study assessments or compliance 8. Currently pregnant, nursing, or planning to become pregnant during the study 9. Clinically significant medical disease that, in the opinion of the investigator, would make participation in a clinical study inappropriate. This includes any psychiatric or other conditions that would constitute a contraindication to participation in the study 10. Currently on neuroleptic agent \[e.g., gabapentin, pregabalin (Lyrica), duloxetine (Cymbalta) etc.\] 11. Inadequate sensory function on the foot (monofilament test) 12. Chronic opioid use in the last 30 days (≥30 morphine equivalents/ day) In addition, the subject may be withdrawn from the study if the subject meets the following criterion during or post-surgery: 13. Any clinically significant event or condition uncovered during the surgery (e.g., excessive bleeding, acute sepsis) that, in the opinion of the investigator, renders the subject medically unstable or complicates the subject's post-operative course
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Magnitude of analgesic effect | 0 hours to 96 hours | Area under the Curve of the NRS Pain intensity scores from 0 hours to 96 hours post-surgery. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Total Postsurgical Opioid Consumption | 0 hours to 96 hours | Total Postsurgical opioid consumption from 0 hours to 96 hours post-surgery |
Outcome results
None listed